Agents
Certara embeds NVIDIA's new BioNeMo Agent Toolkit into model-informed drug development
On July 7, 2026, Certara (Nasdaq: CERT) integrated NVIDIA's newly announced BioNeMo Agent Toolkit into its drug-development platform, letting specialized agents reason over Certara's biosimulation models and datasets to optimize dosing, interrogate clinical data, simulate trials, evaluate ADMET, and assemble regulatory-ready evidence with scientists kept in the decision loop. It is a concrete vertical deployment of agentic AI into regulated pharma R&D. The pattern — domain-specific agent toolkits rather than general chatbots — is how enterprises are actually operationalizing agents.
Source
↳ Follow the thread